Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Subita Mangru

Adolescent Medicine Millburn, NJ Medical Doctor

NPI 1043279193 CMS profile 228287

159 Millburn Ave, Millburn, NJ 07041

Open in the dashboard

General payments

$2,959

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Subita Mangru of Millburn, NJ is reported in the CMS Open Payments database as having received $2,959 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $425 22
2024 General $141 8
2023 General $177 11
2022 General $171 13
2021 General $163 11
2020 General $1,681 16
2019 General $202 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Subita Mangru
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Subita Mangru were reported at $425. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Subita Mangru Adolescent Medicine median Middle half National median
2019 $202 $95 $36–$198 $163
2020 $1,681 $50 $23–$111 $114
2021 $163 $67 $27–$179 $132
2022 $171 $79 $29–$189 $149
2023 $177 $100 $39–$194 $160
2024 $141 $93 $38–$195 $164
2025 $425 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $1,712 18 payments
  2. Merck Sharp & Dohme Corporation $299 20 payments
  3. Sanofi Pasteur Inc. $242 12 payments
  4. kaleo, Inc. $191 13 payments
  5. Sobi, Inc $100 7 payments
  6. ALK-Abello, Inc $70 4 payments
  7. Seqirus USA Inc $64 4 payments
  8. ARS Pharmaceuticals Operations, Inc. $58 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $43 3 payments
  10. Arbor Pharmaceuticals, Inc. $30 2 payments
  11. Other $150 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,500 2 payments
  2. Food and Beverage $1,459 94 payments
Products named General payments · program years 2019–2025
  1. TRUMENBA $1,568 7 payments
  2. GARDASIL 9 $242 16 payments
  3. BEYFORTUS $177 8 payments
  4. AUVI-Q $174 12 payments
  5. VAXNEUVANCE $155 10 payments
  6. VAXELIS $133 9 payments
  7. EUCRISA $129 10 payments
  8. MENQUADFI $103 5 payments
  9. ROTATEQ $101 7 payments
  10. SYNAGIS $100 7 payments
  11. Other $1,222 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record